
|Videos|March 31, 2017
Novel Agents in Pancreatic Cancer
Author(s)Philip A. Philip, MD, PhD
This video covers the latest research in pancreatic cancer, including the possible role of PARP inhibitors, immunotherapy, and the novel drug PEGPH20.
Advertisement
In this video, Philip A. Philip, MD, PhD, of the Barbara Ann Karmanos Cancer Institute in Detroit, discusses the latest research developments and progress in the treatment of pancreatic cancer.
Philip touches on newer chemotherapy regimens such as FOLFIRINOX and gemcitabine plus nab-paclitaxel and highlights immunotherapy in this setting and targeted agents such as PARP inhibitors and a novel drug, pegylated recombinant human hyaluronidase (PEGPH20).
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
I-DXd Earns FDA Priority Review in Extensive-Stage Small Cell Lung Cancer
2
FDA Grants Fast Track Designation to Daretabart for High-Risk Neuroblastoma
3
Daraxonrasib Shows "Unprecedented" Survival in Pretreated Pancreatic Cancer
4
REGN5668 Combo Yields Preliminary Activity in Recurrent Ovarian/Endometrial Cancer
5























































